Aprogen Osteoarthritis Drug AP209 Targets First Patient Dosing in Early August

Aprogen said the clinical trial approval process is under way for AP209, its osteoarthritis drug candidate, and that patient dosing is scheduled for early August. The company submitted its clinical trial application to South Korea’s Ministry of Food and Drug Safety in March and is currently in consultation and supplementation procedures. Aprogen expects clinical approval as early as late May or, at the latest, early June. If approval is granted and patient dosing begins as planned, AP209 would move into the clinical-stage phase of development. The company’s timeline may change depending on the progress of discussions and requested supplements with the regulator. Source: mk.co.kr